Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
about
Literature-based discovery of new candidates for drug repurposing.Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
P2860
Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@en
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@nl
type
label
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@en
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@nl
prefLabel
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@en
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@nl
P2093
P2860
P1433
P1476
Rapamycin combined with celeco ...... h downregulating mTOR pathway.
@en
P2093
P2860
P2888
P304
P356
10.1007/S13277-014-1820-5
P577
2014-03-30T00:00:00Z